Prodrug stimulant lisdexamfetamine dimesylate (Vyvanse, Shire) will be considered a Schedule II substance, according to recent word from DEA.
Prodrug stimulant lisdexamfetamine dimesylate (Vyvanse, Shire) will be considered a Schedule II substance, according to recent word from DEA. This marks the final step in the approval process for the drug, which is expected to launch in the second quarter of this year. Vyvanse was approved by the FDA in February for the treatment of ADHD and is thought to have a lower abuse potential than existing stimulants used to treat the disorder.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.